Welcome to our dedicated page for BioAge Labs news (Ticker: BIOA), a resource for investors and traders seeking the latest updates and insights on BioAge Labs stock.
BioAge Labs, Inc. develops clinical-stage biopharmaceutical candidates for cardiometabolic diseases by targeting the biology of human aging. Its news centers on BGE-102, a potent, orally available, brain-penetrant small-molecule NLRP3 inhibitor being developed for cardiovascular risk and retinal diseases, including diabetic macular edema.
Recurring updates cover Phase 1 biomarker and tolerability data, indication development for inflammation-driven disease, and research into long-acting injectable and oral small-molecule APJ agonists for obesity. BioAge also reports financial results, public offerings, R&D presentations, and collaborations that use its human longevity data platform to identify metabolic-aging pathways.
BioArctic (NASDAQ STOCKHOLM:B) announced a research and collaboration agreement with Eli Lilly to combine BioArctic's BrainTransporter technology with an undisclosed Lilly neurodegeneration drug candidate. BioArctic receives USD 30 million upfront, is eligible for up to USD 770 million in milestones, plus tiered mid-single digit royalties.
Lilly will handle global development and commercialization. This is BioArctic's fourth BrainTransporter collaboration, while it retains platform rights outside the four deals. The project uses an investigational agent, with no assurance of clinical success or regulatory approval.
BioAge Labs (Nasdaq:BIOA) has dosed the first participant in QUELL-CV, a randomized, double-blind, placebo-controlled Phase 2 proof-of-concept trial of oral NLRP3 inhibitor BGE-102 in adults at elevated cardiovascular risk.
The 12-week trial will enroll ~160 participants across four arms to evaluate three once-daily doses versus placebo, with percent change in high-sensitivity C-reactive protein (hsCRP) as the primary endpoint and topline data expected in the second half of 2026.
BioArctic (Nasdaq Stockholm: BIOA B) issued 5,000 Class B shares in May 2026 through exercise of 5,000 stock options from the 2019/2028 program. As of May 29, 2026, BioArctic has 88,724,485 shares outstanding and 218,324,449 votes in total.
The share capital comprises 74,324,489 listed Class B shares and 14,399,996 unlisted Class A shares. Each A share carries ten votes and each B share one vote.
BioArctic (Nasdaq Stockholm: BIOA B) held its AGM on 28 May 2026 and approved the 2025 income statement and balance sheet, a dividend of SEK 2 per share with record date 1 June 2026, and discharge of the board and CEO.
Shareholders re-elected six directors, elected two new members, and re-elected the chair. The AGM authorised the board to issue new shares, warrants and convertibles of up to 10% of share capital, adopted a three-year PSU incentive program of up to 235,000 units with related hedging, and updated senior executive remuneration guidelines.
BioArctic (NASDAQ Stockholm: B) reported that partner Eisai presented a simulation of potential future Leqembi sales at its Investor Relations Day.
According to Eisai, simulated Leqembi sales reach around JPY 300 billion (≈SEK 17.6 billion) in FY2028, ending March 2029. The disclosure was made under EU Market Abuse Regulation rules.
BioAge Labs (NASDAQ:BIOA) will participate in two upcoming investor conferences. Management will join fireside chats and one-on-one meetings at the Jefferies Global Healthcare Conference in New York on June 4, 2026, and the Goldman Sachs Global Healthcare Conference in Miami Beach on June 8, 2025.
Live webcasts will be accessible via registration links, with replays available for 30 days in the investor section of BioAge’s website.
BioArctic (Nasdaq Stockholm: BIOA B) announced that partner Eisai projects Leqembi sales of JPY 143.5 billion (about SEK 8.4 billion) for FY 2026 (April 2026–March 2027), a 63% increase year over year.
This is expected to generate roughly SEK 880 million in royalties to BioArctic. The companies are preparing joint commercialization of Leqembi for Alzheimer's disease in the Nordic region.
BioArctic (NASDAQ Stockholm: BIOA B) will publish its first quarter 2026 report for January–March on May 20, 2026 at 8:00 a.m. CET. A webcast and teleconference in English with the CEO and CFO will follow at 9:30 a.m. CET, including a Q&A session.
The webcast requires online registration for written questions, while verbal questions are handled via a separate teleconference registration. A replay will be available on BioArctic's investor website after the presentation.
BioAge (NASDAQ: BIOA) reported positive topline Phase 1 data for oral NLRP3 inhibitor BGE-102, showing median hsCRP reductions of 86% across 60 mg and 120 mg once-daily cohorts and 87–93% of participants reaching hsCRP <2 mg/L. BGE-102 was well tolerated. The company plans two mid-2026 proof-of-concept trials (cardiovascular risk Phase 2 and DME Phase 1b/2a) with data expected by end-2026 and mid-2027. BioAge completed an upsized follow-on offering raising $132.3M. Q1 2026: collaboration revenue $2.8M, R&D $20.4M, G&A $7.7M, net loss $22.3M ($0.52), cash $384.9M; runway through 2029.
BioArctic (NYSE:B) reports that the FDA extended the PDUFA date for the sBLA for Leqembi Iqlik to August 24, 2026 after requesting additional information, which the agency classified as a major amendment and added a three‑month review period. The FDA has not raised approvability concerns to date.
Leqembi maintenance subcutaneous dosing received FDA action on August 26, 2025, and Leqembi is approved by more than 50 regulatory authorities worldwide. BioArctic and Eisai continue plans for joint Nordic commercialization.